ArticleNaunyn-Schmiedeberg's archives of pharmacology2026
Evaluation of sulfobutylether-β-cyclodextrin complex loaded dissolving microneedles-mediated delivery of fluticasone propionate for atopic dermatitis.
Article in Naunyn-Schmiedeberg's archives of pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Atopic dermatitis (AD) is a chronic inflammatory skin disease that often requires corticosteroid therapy; however, conventional topical delivery can be limited by poor drug solubility. This study aimed to fabricate and evaluate sulfobutylether-β-cyclodextrin (SBE-β-CD) inclusion complex-loaded dissolving microneedles for the microneedle delivery of fluticasone propionate (FP) in AD. The aqueous solubility of FP was enhanced through complexation with SBE-β-CD, followed by incorporation of the resulting inclusion complex into dissolving microneedles. The fabricated MNs were comprehensively characterized by scanning electron microscopy (SEM), Fourier transform infrared spectroscopy (FTIR), drug content analysis, insertion testing, in vitro release studies, and in vivo evaluation over a period of 15-day treatment in six groups of BALB/c mice, including primary comparison groups (the vehicle and commercial topical controls). SEM confirmed uniform microneedle morphology; FTIR indicated between FP and the formulation components. Drug content showed 98% recovery; each MN patch contained 56.93 µg FP per 7.84 mm
Indexed as
Identifiers
42608561What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.